|
 |
| |
|
GBI focuses exclusively on the pharmaceutical, healthcare, and biotechnology industries in China. With an understanding of ongoing policy shifts, a global perspective, and a granular knowledge of China's marketplace, players, and practices, GBI maintains a substantial advantage over diversified consulting firms.
|
| |
| Experience |
| Since our inception in 2002, we have executed projects ranging across multiple areas of the healthcare value chain. Our accumulated case work provides us with a unique perspective, allowing us in many cases to accelerate timelines, quickly work through common issues, and dig more deeply into relevant detail for our clients. We focus not only on strategic issues, but also the practicalities of implementing strategies in China’s business environment. Experience has shown us that an excellent China strategy is useless without significant input from those versed in the realities and constraints on execution in China. |
| |
| Specific Areas |
- Opportunity assessments for pharmaceutical products in China's market
- Due diligence on companies and products
- Technology and therapeutic area landscape assessment
|
| |
 |
| Case Studies |
| |
Global MNC client with limited presence in China was already in negotiations with several pharmaceutical company targets |
| |
| Client needed to understand key aspects of targets
|
- Value of the sales channel and organization
- Attractiveness of the portfolio in context of acquirer
- Regulatory performance/speed compared to peers
- Red flags in management, organization, or market performance
|
|
|
GB executed project by analyzing SOURCE and outside data |
- Physician interviews and surveys
- Pricing and tendering analysis for competition
- Comparables analysis in investment and sales performance
- Pipeline analysis for similar products
- Estimation of timing of regulatory issues
|
|
|
| Regional client with US phase III product needed to assess the value of China opportunity to prioritize development and commercialization |
| |
| Client needed to understand value points
|
- Product lifecycle projections and peak sales
- Current prescribing patterns and competitive landscape
- Physician openness and attractiveness of product
- Pricing and tendering scenarios
- Timing of key milestones given different investment scenarios
- Pipeline analysis and future landscape projections
|
| |
| GB executed project by analyzing SOURCE and outside data
|
- Physician interviews and surveys
- Pricing and tendering analysis for competition
- Physician openness and attractiveness of product
- Comparables analysis in investment and sales performance
- Pipeline analysis for similar products
- Estimation of timing of regulatory issues
|
